PEPFAR

What PEPFAR does

PEPFAR (President's Emergency Plan for AIDS Relief) is a U.S. government foreign assistance initiative launched in 2003 by President George W. Bush and administered by the U.S. Department of State through its Bureau of Global Health Security and Diplomacy. It is the largest commitment by any nation to address a single disease, with cumulative U.S. government funding exceeding $100 billion since inception. As of Q3 2025, PEPFAR provides antiretroviral therapy to 20.6 million people and operates through bilateral health agreements with 32 partner countries totaling $20.3 billion in commitments, alongside a delivery network of implementing partners, HIV clinics, and supply chain infrastructure reaching 50+ countries.

The program's core interventions include antiretroviral therapy delivery, HIV testing and counseling, prevention tools such as oral PrEP, and—more recently—long-acting injectable HIV prevention drugs including Gilead's lenacapavir (twice-yearly dosing) and ViiV's cabotegravir. The flagship DREAMS initiative targets adolescent girls and young women aged 15-24 in sub-Saharan Africa, having reached 2.3 million beneficiaries and reduced new infections among participants by 63% between 2020-2023. Underlying technology centers on pharmaceutical procurement logistics via the USAID Global Health Supply Chain Program, laboratory diagnostics, healthcare worker training, and clinic infrastructure rather than proprietary software or digital platforms. Strategic partners include UNAIDS, the Global Fund, CHAI, Unitaid, Wits RHI, Gilead Sciences, ViiV Healthcare, and Merck.

PEPFAR's business model is congressional appropriations-based—funded entirely through U.S. government allocations and providing all services at no cost to patients through implementing partners and supported healthcare facilities. The program is currently under acute stress following the Trump administration's January 2025 funding halt and 30% top-line cut from $6.7 billion to $4.6 billion, with permanent cessation of PEPFAR funding announced for early 2027. Operational disruption has been severe: 1,700+ HIV treatment sites have closed globally, 1,714 clinics and community providers have shut down per amfAR surveys, new patient enrollment fell 59% in Kenya/Uganda/Tanzania within five weeks of funding withdrawal, and mortality attributed to the cuts exceeds 780,000 deaths in northeastern Nigeria and 570,000 deaths in 2025.

Name

PEPFAR

Legal name

U.S. President's Emergency Plan for AIDS Relief (PEPFAR)

Website

https://state.gov

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

PEPFAR is a U.S. government initiative administered through the State Department that funds antiretroviral therapy, HIV prevention programs, and healthcare infrastructure across 50+ countries, currently serving approximately 20.6 million people living with HIV globally.

Ownership category

akta.pro rank

Product category

Global Health Programs / HIV/AIDS Treatment and Prevention

NAICS

Social Assistance (624), Grantmaking and Giving Services (81321), Voluntary Health Organizations (813212)

SIC

Services-Social Services (8300), Hospital & Medical Service Plans (6324)

akta.pro primary industry

Global Health Financing Mechanisms & Pooled Funds (HLAJAOAC)

akta.pro secondary industries

Disease-Specific Global Programs (HIV/TB/Malaria/NTDs) (HLAJAKAF), HIV/AIDS Medicine (HLAKAGAB)

Keywords

• HIV/AIDS treatment programs
• Antiretroviral therapy funding
• Global health assistance
• HIV prevention programs
• Public health funding

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Supply Chain, Personnel, Infrastructure, Others

Distribution channels3 records

Marketing channels3 records

Core offering

PEPFAR funds and coordinates global HIV/AIDS prevention, treatment, and care programs through bilateral agreements with partner governments, implementing partners, and healthcare facilities. The program provides free antiretroviral therapy to approximately 20.6 million people, supports HIV testing and counseling services, delivers prevention tools including PrEP and long-acting injectable drugs (lenacapavir, cabotegravir), funds laboratory diagnostic capabilities, and supports healthcare worker training and clinic infrastructure in 50+ countries.

Product overview

PEPFAR (President's Emergency Plan for AIDS Relief) is a United States government initiative to combat HIV/AIDS globally. The program provides funding for antiretroviral therapy to approximately 20.6 million people, supports HIV testing services, prevention programs including PrEP, and health commodity supply chain management through partnerships with organizations such as the Global Fund, CHAI, Unitaid, and Wits RHI. PEPFAR also funds health systems strengthening and laboratory diagnostic capabilities in partner countries.

Differentiator

Problem solved

Functional benefit

Products and services

• DREAMS Initiative A comprehensive HIV prevention program targeting adolescent girls and young women aged 15-24 in sub-Saharan Africa, providing layered prevention services including PrEP access, education, economic support, and community mobilization.
• PEPFAR Bridge Plan A transitional funding mechanism to maintain continuity of HIV/AIDS treatment services in South Africa during funding uncertainty, ensuring uninterrupted antiretroviral therapy for patients reliant on PEPFAR-supported programs.
• USAID Global Health Supply Chain Program (GHSC-PSM) A supply chain management program that delivers HIV medications and health commodities to partner countries while strengthening national pharmaceutical and medical supply chain systems.
• Bilateral Health Agreements Program Country-level funding and coordination agreements between the U.S. Government and partner national governments, establishing multi-year commitments for HIV/AIDS treatment, prevention, and health systems strengthening.
• Antiretroviral Therapy (ART) Program The foundational PEPFAR service providing free antiretroviral therapy to people living with HIV in partner countries, reaching 20.6 million people as of Q3 2025 and supporting treatment continuity across 1,700+ HIV treatment sites globally.
• Lenacapavir Long-Acting Injectable PrEP Program A long-acting injectable HIV pre-exposure prophylaxis (PrEP) delivery program providing twice-yearly lenacapavir injections as an alternative to daily oral PrEP, with rollout across early adopter African countries.

Quantifiable outcome

• 20.6 million people provided antiretroviral therapy in Q3 2025
• +3 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

16 partnerships are on record, tiered core and minor.

• UNAIDScoreStrategic or Co-development PartnerUNAIDS coordinates global HIV response and works with PEPFAR on global HIV targets, country partnerships, and the 95-95-95 treatment goals. UNAIDS warned of severe impacts from funding cuts, reporting international HIV funding declined by over US$1.5 billion to US$7.3 billion in 2025.
• Gilead SciencescoreStrategic or Co-development PartnerGilead's lenacapavir (long-acting HIV prevention drug) launched in African nations with support from Global Fund and PEPFAR. Early adopters in 10 African nations have initiated over 11,000 people on the drug, with projections exceeding 600,000 users by year-end.
• ViiV HealthcareminorStrategic or Co-development PartnerPharmaceutical company cited at AIDS 2026 for licensing decisions contributing to declines in HIV prevention and treatment access alongside Gilead and Merck.
• MerckminorStrategic or Co-development PartnerPharmaceutical company cited at AIDS 2026 alongside Gilead and ViiV Healthcare for licensing decisions affecting global HIV treatment access.
• Global FundcoreStrategic or Co-development PartnerGlobal Fund co-finances and supports lenacapavir rollout in low- and middle-income countries alongside PEPFAR. Both organizations provide funding and drug supply for HIV treatment and prevention programs globally.
• UnitaidcoreStrategic or Co-development PartnerUnitaid facilitates lenacapavir expansion through market updates and implementation studies to lower costs and strengthen delivery models in early adopter countries.
• CHAI (Clinton Health Access Initiative)coreStrategic or Co-development PartnerCHAI facilitates lenacapavir expansion through market updates and implementation studies to lower costs and strengthen delivery models alongside Unitaid and Wits RHI.
• Wits RHI (Wits Reproductive Health and HIV Institute)coreStrategic or Co-development PartnerWits RHI facilitates lenacapavir expansion through market updates and implementation studies alongside CHAI and Unitaid to lower costs and strengthen delivery models.
• Makerere University - John Hopkins University Research CollaborationcoreStrategic or Co-development PartnerResearch collaboration conducted trials showing 100% effectiveness of lenacapavir, supporting Uganda's rollout of long-acting HIV prevention drugs.
• amfAR (The Foundation for AIDS Research)coreStrategic or Co-development PartneramfAR conducted survey finding 1,714 clinics and community providers shut down due to PEPFAR funding cuts, tracking impact of funding reductions on HIV service delivery.
• East Africa IeDEA ConsortiumcoreStrategic or Co-development PartnerEast Africa IeDEA consortium provided patient-level data from nearly 103,000 people at 189 clinics in Kenya, Uganda, and Tanzania showing 59% decline in new patient enrollment following funding withdrawal.
• UCSF (University of California, San Francisco)coreStrategic or Co-development PartnerUCSF researchers conducted study finding 59% decline in new patient enrollment and 33% drop in viral load testing across HIV clinics in Kenya, Uganda, and Tanzania within five weeks of US government funding withdrawal.
• Jomo Kenyatta University of Agriculture and TechnologycoreStrategic or Co-development PartnerResearchers from this university found approximately 77,000 fewer children received US-supported HIV treatment globally in year to October 2025, a 14% year-on-year decline linked to funding cuts.
• USAIDcoreStrategic or Co-development PartnerUSAID runs the Global Health Supply Chain Program-Procurement and Supply Management (GHSC-PSM) project funded by PEPFAR to deliver health commodities and strengthen supply chain systems for HIV/AIDS, malaria, and maternal health.
• CDC (U.S. Centers for Disease Control and Prevention)coreStrategic or Co-development PartnerCDC supported by PEPFAR collaborates with Sierra Leone Ministry of Health to strengthen public health capacity and combat HIV and TB, providing HIV testing to nearly 117,000 individuals and treating over 24,000 people living with HIV in FY2024.
• GavicoreStrategic or Co-development PartnerUS re-engaged with Gavi in June 2026 following initial freeze, as part of the 'America First Global Health Strategy' for health cooperation.

Scale indicators15 records

Recent moves6 records

Expansion highlights4 records

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PEPFAR